All In Biotech

Drug Trial Radar · NCT01177098

Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Last checked: Nov 20, 2026Latest source record: Mar 29, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 561 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

561

Actual

Start

Oct 2010

Primary completion

Feb 2012

Study completion Feb 2012

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Aug 6, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of bimatoprost/timolol formulation A ophthalmic solution with Ganfort® (bimatoprost 0.03%/timolol 0.5% ophthalmic solution) once daily for 12 weeks in patients with glaucoma or ocular hypertension.

Conditions

  • Glaucoma
  • Ocular Hypertension

Interventions

  • bimatoprost /timolol formulation A fixed combination ophthalmic solutionDrug

    One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.

  • bimatoprost/timolol fixed combination ophthalmic solutionDrug

    One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12Time frame: Baseline, Week 12
  2. Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 2Time frame: Week 2
  3. Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 6Time frame: Week 6
  4. Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12Time frame: Week 12

Locations

9 sites in 9 countries. Site status is shown where the registry gives one.

  • Site not named

    Artesia, California

  • Site not named

    Sydney, New South Wales, Australia

  • Site not named

    Brno, Czechia

  • Site not named

    Leipzig, Germany

  • Site not named

    Budapest, Hungary

  • Site not named

    Tel Aviv, Israel

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Valencia, Spain

  • Site not named

    London, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.